Washington, DC 20549


                                    FORM 8-K

                                 CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(d) OF
                           THE SECURITIES ACT OF 1934

         Date of report (Date of earliest event reported): May 29, 2002

                               CYTOGEN CORPORATION
               (Exact Name of Registrant as Specified in Charter)

           Delaware                     000-14879                 222322400
(State or Other Jurisdiction     (Commission File Number)       (IRS Employer
      of Incorporation)                                      Identification No.)

600 College Road East, CN 5308, Princeton, NJ                            08540
(Address of Principal Executive Offices)                              (Zip Code)

                                 (609) 750-8200
                         (Registrant's telephone number,
                              including area code)

          (Former Name or Former Address, if Changed Since Last Report)

     Item 5.     Other Events.

     On May 29, 2002, Cytogen Corporation (the "Company") issued a press release
reporting the Company's financial guidance and outlining the Company's strategic
planning and  operations  for 2002.  Subsequently,  on May 30, 2002, the Company
issued a joint  press  release  with  Draximage  Inc.,  the  radiopharmaceutical
subsidiary  of DRAXIS  Health  Inc.,  announcing  the launch of DRAXIS  Health's
BrachySeed  Palladium-103  product in the United  States  for the  treatment  of
prostate cancer.

     Each such press  release is  attached  hereto as Exhibit  99.1 and  Exhibit
99.2, respectively,  and each is incorporated herein by reference. The foregoing
description of each such press release is qualified in its entirety by reference
to each such respective document.

     Item 7.    Financial Statements, Pro Forma Financial Information and

     (c) Exhibits.

           Exhibit No.       Description
           -----------       -----------
           99.1              Press release of the Company dated May 29, 2002
           99.2              Press release of the Company dated May 30, 2002


     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                              Cytogen Corporation

                                              By: /s/ Lawrence R. Hoffman
                                                  Lawrence R. Hoffman,
                                                   Chief Financial Officer

Date:  May 30, 2002